GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles
Authors:
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 143, 105096
Abstract
No abstract availableKeywords
Funding Information
- Dutch Cancer Society (RUG 2009-4579, RUG 2011-5156)
- efro (068/073)
This publication has 18 references indexed in Scilit:
- The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcomeJournal of Translational Medicine, 2015
- Tumor‐infiltrating CD14‐positive myeloid cells and CD8‐positive T‐cells prolong survival in patients with cervical carcinomaInternational Journal of Cancer, 2013
- Prevention and Treatment of Papillomavirus-Related Cancers Through ImmunizationAnnual Review of Immunology, 2011
- Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competitionGene Therapy, 2007
- A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancerGene Therapy, 2007
- Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapyJournal of Clinical Virology, 2006
- Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA PhenotypeClinical Cancer Research, 2005
- Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of ImmunizationAntiviral Therapy, 2004
- Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7Gene Therapy, 2002
- Human Papillomavirus Infection in Women Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997